Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.

Journal of experimental & clinical cancer research : CR - 23 Mar 2020

Guan Luyao, Li Zhang, Xie Feifei, Pang Yuzhi, Zhang Chenyun, Tang Haosha, Zhang Hao, Chen Chun, Zhan Yaying, Zhao Ting, Jiang Hongyuan, Jia Xiaona, Wang Yuexiang, Lu Yuan

Abstract excerpt

BACKGROUND: Epithelial ovarian cancer (EOC) is a highly lethal malignancy. Improvement in genetic characterization of EOC patients is required to propose new potential targets, since surgical resection coupled to chemotherapy, presents several limits such as cancer recurrence and drug resistance. Targeted therapies have more efficacy and less toxicity than standard treatments. One of the most relevant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Mice, Nude

Share to Molecular Targeted Therapy

Share to NIH 3T3 Cells

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins c-ret

Source

Open in PubMed Open full text

Identifiers

PMID: 32293499
DOI: 10.1186/s13046-020-01557-3
PMCID: PMC7092606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.PMID 32293499Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read ↗

Progresses Toward Precision Medicine in RET-altered Solid Tumors.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Precision oncology for RET-related tumorsSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.Semantic proximity Read ↗

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Semantic proximity Read ↗

Modeling the Effects of Single Nucleotide Polymorphisms (SNPs) on the Structure and Function of the Human RET Gene: An In Silico Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.